PD 1
Alternative Names: Anti-dyskinesia therapeutic - BIO3 Research; PD-1Latest Information Update: 16 Jan 2022
Price :
$50 *
At a glance
- Originator Bio3 Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Drug-induced dyskinesia
Most Recent Events
- 12 Oct 2005 Discontinued - Phase-I for Drug-induced dyskinesia in Italy (unspecified route)
- 06 Jul 2004 Bio3 Research is seeking worldwide partners for the development of PD 1
- 06 Jul 2004 Phase-I clinical trials in Drug-induced dyskinesia in Italy (unspecified route)